Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. 1997

Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
The Second Department of Internal Medicine, Ehime, University School of Medicine, Shige-nobu-cho, Onsen-gun, Japan.

To elucidate whether there is a difference in the progression of target-organ damage between primary aldosteronism and essential hypertension, we compared left ventricular hypertrophy and extracardiac target-organ damage in 23 patients with primary aldosteronism and 116 patients with essential hypertension. The severity of hypertensive retinopathy and the renal involvement in primary aldosteronism were subclinical and similar to those in essential hypertension without left ventricular hypertrophy but significantly milder than those in essential hypertension with left ventricular hypertrophy. There was a strongly significant correlation between the degree of left ventricular mass index and the severity of hypertensive retinopathy and renal involvement independent of office blood pressure in essential hypertension. In contrast, left ventricular hypertrophy markedly progressed despite the mild extracardiac target-organ damage in primary aldosteronism. Left ventricular end-diastolic dimension index in primary aldosteronism (3.16+/-0.50 cm/m2) was significantly larger than in essential hypertension without (2.87+/-0.23) and with (2.88+/-0.22) left ventricular hypertrophy. On the other hand, there was no difference in extracardiac target-organ damage between 13 primary aldosteronism patients with eccentric left ventricular hypertrophy and the 26 essential hypertensive patients with eccentric left ventricular hypertrophy. The results suggest that predominantly volume load, be it due to aldosteronism or other mechanisms, resulting in eccentric left ventricular hypertrophy is less likely to cause extracardiac target-organ damage than hemodynamic or nonhemodynamic mechanisms resulting in concentric left ventricular hypertrophy.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000450 Aldosterone A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. Aldosterone, (+-)-Isomer,Aldosterone, (11 beta,17 alpha)-Isomer

Related Publications

Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
January 2003, Blood pressure,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
December 2001, Journal of hypertension,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
January 2002, Journal of hypertension,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
November 2018, Annales de cardiologie et d'angeiologie,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
May 2024, Journal of clinical hypertension (Greenwich, Conn.),
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
December 2018, The Journal of clinical endocrinology and metabolism,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
March 2018, Journal of hypertension,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
August 1988, The American journal of cardiology,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
January 2021, Frontiers in cardiovascular medicine,
Y Shigematsu, and M Hamada, and H Okayama, and Y Hara, and Y Hayashi, and K Kodama, and K Kohara, and K Hiwada
January 2003, American journal of hypertension,
Copied contents to your clipboard!